# Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim

> **NCT01182675** · PHASE2 · TERMINATED · sponsor: **University of California, San Francisco** · enrollment: 7 (actual)

## Conditions studied

- Severe Combined Immunodeficiency

## Interventions

- **DRUG:** Transplant Conditioning with Mobilization Only
- **DRUG:** Transplant Conditioning with Mobilization and Alemtuzumab

## Key facts

- **NCT ID:** NCT01182675
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-08
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Insufficient evidence of efficacy
- **Last updated:** 2018-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01182675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01182675, "Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01182675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*